NCT01357603已完成1 期
A Randomized, Double-blind, Two Period, Cross Over Glucose Clamp Study to Test for Bioeqivalence Between Two Long Acting Insulin Analogs-Wockhardt's Glaritus™ (Insulin Glargine) and Lantus (Insulin Glargine) in Subjects With Type 1 Diabetes
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Wockhardt
- 入组人数
- 111
- 试验地点
- 2
- 主要终点
- Bioequivalence based on Pharmacokinetic parameter:AUC INS-GLR 0-24h.
研究概览
简要总结
The aim of this trial is to demonstrate bioequivalence of Glaritus® to Lantus® with regard to its total and to its maximum serum insulin concentrations.
详细描述
The purpose of this study is to test for bioequivalence based on the pharmacokinetic parameter AUC INS-GLR 0-24h and on pharmacodynamic parameter AUC GIR 0-24h between the two long-acting insulin glargine formulations, Lantus® and Wockhardt's Glaritus® in subjects with type1 diabetes as well as assessing safety and local tolerability of the two insulin preparations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Health Services Research
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects with type 1 diabetes ≥12 months.
- •HbA1c ≤9% by local laboratory analysis (one retest within a week is permitted with the result of the last test being conclusive).
- •Age ≥18 and ≤60 years.
- •Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Investigator.
- •Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).
排除标准
- •Previous participation in this trial, or participation in other clinical trials within the last 30 days.
- •Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures (e.g. intrauterine device (IUD) that has been in place for at least 3 months, or sterilization, or the oral contraceptive pill, which should have been taken without difficulty for at least 3 months, an approved hormonal implant or double barrier method including male condoms used plus spermicide, diaphragm with spermicide plus male condom, cap with spermicide plus male condom).
- •History of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial drug to the subject. In particular, subjects with significant cardiovascular disease, anemia (hemoglobin below the lower limit of normal) or hemoglobinopathy will not be allowed to enter the trial.
- •Cardiac problems defined as decompensated heart failure (New York Heart Association (NYHA) class III and IV) at any time and/or angina pectoris within the last 12 months and/or acute myocardial infarction at any time.
- •Clinically significant abnormal ECG at screening, as judged by the Investigator.
- •History of alcohol or drug abuse in the past five years.
- •Any positive reaction of drug abuse.
- •Hepatitis B or C or HIV positive.
- •Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
- •History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
- •Regular cigarette smoker, defined as smoking >1 pack/day and unable to refrain from smoking during the in house period.
- •Known or suspected allergy to trial product or related products.
- •Any disease or condition that, in the opinion of the Investigator, would represent an unacceptable risk for the subject's safety.
结局指标
主要结局
Bioequivalence based on Pharmacokinetic parameter:AUC INS-GLR 0-24h.
时间窗: over 24hrs post dose
Bioequivalence based on Pharmacodynamic parameter: AUC GIR 0-24hrs
时间窗: over 24hrs post dose
Pharmacokinetic Parameters: Maximum concentration (Cmax)
时间窗: over 24hrs post dose
次要结局
- Safety parameters(till 24 hrs post-dose)
- Pharmacodynamic parameters: Area under curve glucose infusion rate from 0-24hrs(over 24hrs post dose)
- Pharmacokinetic parameter: Area under curve from 0-24hrs(over 24hrs post dose)
- Pharmacokinetic Parameters: tmax and t1/2(over 24hrs post dose)
- Pharmacodynamic parameter: GIR max and tGIR max(over 24hrs post dose)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Study in Adults With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01421459Eli Lilly and Company759
已完成
3 期
Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia BHemophilia BNCT00093210Wyeth is now a wholly owned subsidiary of Pfizer
已完成
2 期
Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes SubjectsType 1 Diabetes MellitusNCT02408705Medical University of Graz14
已完成
3 期
A Study of Dulaglutide (LY2189265) in Participants With Type II DiabetesDiabetes Mellitus, Type 2NCT02152371Eli Lilly and Company300
已完成
3 期
A Trial of the ALK Grass Tablet in Subjects With HayfeverAllergyNCT00227279ALK-Abelló A/S634